Logo

Jacobio Receives CDE’s IND Approval for Combination Therapy of KRAS G12C and Cetuximab Injection in China

Share this

Jacobio Receives CDE’s IND Approval for Combination Therapy of KRAS G12C and Cetuximab Injection in China

Shots:

  • The preclinical results showed that the combination JAB-21822 + Cetuximab can improve the anti-tumor activity of JAB-21822 in CRC tumor models, make tumor regression, and delay tumor re-growth after the cessation of using the drug
  • Jacobio plans to initiate a P-I/II, open-label, multi-center, dose-escalation, and expansion clinical trial in China to assess the safety, tolerability, and preliminary efficacy of the combination therapy in KRAS G12C mutant patients with advanced CRC
  • JAB-21822 is approved for 5 clinical trials in China and the US, which includes monothx and combination therapies (with either PD-1 Ab or Cetuximab) to treat KRAS G12C advanced solid tumors mutant patients including NSCLC and colorectal cancer

Ref: Businesswire | Image: Jacobio

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions